NC
GYRE icon

Nexthera Capital’s Gyre Therapeutics GYRE Stock Holding History

Nexthera Capital’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-50,135
Closed -$2.97M – 26
2018
Q4 		$2.97M Sell
50,135
-68,876
-58% -$5.08M 1.22% 16
2018
Q3 		$9.62M Buy
119,011
+14,096
+13% +$1.12M 1.84% 18
2018
Q2 		$9.18M Buy
104,915
+33,098
+46% +$5.81M 1.42% 21
2018
Q1 		$13.9M Buy
71,817
+30,327
+73% +$5.66M 2.29% 15
2017
Q4 		$4.24M Buy
+41,490
New +$2.12M 0.78% 29

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Nexthera Capital's GYRE Position: Q1 2019 in Review

Nexthera Capital sold out of Gyre Therapeutics (GYRE) in Q1 2019, closing a stake of 50,135 shares — an estimated $2.97M sold.

Nexthera Capital first reported a position in GYRE in Q4 2017 and held it in 5 quarters. The position peaked at $13.9M in Q1 2018. 63 funds tracked by Wall St. Rank hold GYRE as of Q1 2019.

  • Nexthera Capital reported no remaining Gyre Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Nexthera Capital sold 50,135 Gyre Therapeutics shares in Q1 2019, an estimated $2.97M.
  • Nexthera Capital first reported a position in Gyre Therapeutics in Q4 2017 and held it in 5 quarters.
  • Nexthera Capital's Gyre Therapeutics position peaked at $13.9M in Q1 2018.
  • 63 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2019.

Based on Nexthera Capital's 13F filing for Q1 2019, filed 15 May 2019.